Photo from Paolo Tarantino/Twitter
Jul 9, 2023, 09:59
Phase 1 data from the auristatin HER2 ADC PF-06804103 highlight the importance of optimizing the toxicity profile of novel ADCs – Paolo Tarantino
Phase 1 data from the auristatin HER2 ADC PF-06804103 highlight the importance of optimizing the toxicity profile of novel ADCs. The drug showed relevant activity (ORR 30%) for HER2+ BC & GC, but nearly half of the pts discontinued treatment for toxicity.
For article: Click here
Source: Paolo Tarantino/Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 13, 2024, 19:25
Nov 13, 2024, 16:51
Nov 13, 2024, 16:49
Nov 13, 2024, 16:45
Nov 13, 2024, 16:25
Nov 13, 2024, 16:23
Nov 13, 2024, 16:08